Dashboard
Manage Tickers

MNPR Monopar Therapeutics

Nasdaq monopartx.com


$ 83.12 $ 0.35 (0.42 %)    

Tuesday, 11-Nov-2025 15:59:59 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 622.18 $ 0.90 (0.15 %)
DIA $ 479.57 $ 5.59 (1.18 %)
SPY $ 683.15 $ 2.90 (0.43 %)
TLT $ 89.91 $ 0.01 (0.01 %)
GLD $ 381.04 $ -0.09 (-0.02 %)
$ 83.43
$ 82.95
$ 80.00 x 50
$ 96.00 x 2
$ 80.80 - $ 84.28
$ 16.25 - $ 105.00
235,191
na
514.76M
$ 0.76
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-23-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-24-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-25-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-27-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-10-2019 03-31-2019 10-Q
27 02-26-2019 12-31-2018 10-K
28 11-09-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-11-2018 03-31-2018 10-Q
31 03-26-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

chardan-capital-maintains-buy-on-monopar-therapeutics-raises-price-target-to-100
Chardan Capital Maintains Buy on Monopar T...
11/10/2025 12:19:47

Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from ...

leerink-partners-initiates-coverage-on-monopar-therapeutics-with-outperform-rating-announces-price-target-of-115
Leerink Partners Initiates Coverage On Mon...
11/10/2025 11:59:31

Leerink Partners analyst Joseph Schwartz initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Outperform rating a...

reported-sunday-monopar-presents-phase-2-data-showing-rapid-copper-balance-improvement-in-wilson-disease-patients-on-tiomolybdate-choline-at-aasld-2025
Reported Sunday, Monopar Presents Phase 2 ...
11/10/2025 08:10:57

this-monopar-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday
This Monopar Therapeutics Analyst Begins C...
10/13/2025 12:25:51

barclays-initiates-coverage-on-monopar-therapeutics-with-overweight-rating-announces-price-target-of-125
Barclays Initiates Coverage On Monopar The...
10/13/2025 12:05:47

Barclays analyst Etzer Darout initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Overweight rating and announce...

raymond-james-maintains-strong-buy-on-monopar-therapeutics-raises-price-target-to-142
Raymond James Maintains Strong Buy on Mono...
10/06/2025 16:59:18

Raymond James analyst Chris Raymond maintains Monopar Therapeutics (NASDAQ:MNPR) with a Strong Buy and raises the price targ...

oppenheimer-maintains-outperform-on-monopar-therapeutics-raises-price-target-to-115
Oppenheimer Maintains Outperform on Monopa...
10/02/2025 13:31:55

Oppenheimer analyst Andreas Argyrides maintains Monopar Therapeutics (NASDAQ:MNPR) with a Outperform and raises the price ta...

hc-wainwright--co-maintains-buy-on-monopar-therapeutics-raises-price-target-to-105
HC Wainwright & Co. Maintains Buy on Monop...
09/29/2025 14:09:37

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises the ...

piper-sandler-maintains-overweight-on-monopar-therapeutics-raises-price-target-to-95
Piper Sandler Maintains Overweight on Mono...
09/25/2025 16:52:30

Piper Sandler analyst Biren Amin maintains Monopar Therapeutics (NASDAQ: MNPR) with a Overweight and raises the price target...

crowdstrike-to-rally-around-26-here-are-10-top-analyst-forecasts-for-thursday
CrowdStrike To Rally Around 26%? Here Are ...
09/25/2025 12:16:13

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

btig-maintains-buy-on-monopar-therapeutics-raises-price-target-to-104
BTIG Maintains Buy on Monopar Therapeutics...
09/25/2025 11:56:35

BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises the price target from $87 t...

chardan-capital-maintains-buy-on-monopar-therapeutics-raises-price-target-to-85
Chardan Capital Maintains Buy on Monopar T...
09/25/2025 11:52:13

Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises the price target from...

reported-earlier-monopar-highlights-journal-of-hepatology-publication-confirming-alxn1840-rapidly-improved-copper-excretion-in-wilson-disease-patients
Reported Earlier ,Monopar Highlights Journ...
09/24/2025 06:25:51

reported-earlier-monopar-therapeutics-prices-135m-underwritten-offering-of-1034433-common-stock-and-pre-funded-warrants-at-6767-per-share-plans-35m-buyback-of-shares-from-tactic-pharma
Reported Earlier, Monopar Therapeutics Pri...
09/24/2025 06:25:09

lake-street-initiates-coverage-on-monopar-therapeutics-with-buy-rating-announces-price-target-of-106
Lake Street Initiates Coverage On Monopar ...
09/23/2025 14:38:19

Lake Street initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and announces Price Target of $106.

chardan-capital-maintains-buy-on-monopar-therapeutics-maintains-60-price-target
Chardan Capital Maintains Buy on Monopar T...
09/16/2025 11:11:37

Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $60 price target.

btig-reiterates-buy-on-monopar-therapeutics-maintains-87-price-target
BTIG Reiterates Buy on Monopar Therapeutic...
09/15/2025 14:41:09

BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $87 price target.

monopar-to-present-6-year-data-showing-sustained-neurological-improvement-with-alxn1840-in-wilson-disease-on-uwdrs-part-ii-and-iii-at-ana-annual-meeting
Monopar To Present 6-Year Data Showing Sus...
09/14/2025 12:15:57

Monopar Therapeutics Inc. (NASDAQ:MNPR) announced that new data on the long-term neurological efficacy and safety of its invest...

btig-initiates-coverage-on-monopar-therapeutics-with-buy-rating-announces-price-target-of-87
BTIG Initiates Coverage On Monopar Therape...
09/09/2025 10:50:39

BTIG analyst Jeet Mukherjee initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and announces Price ...

raymond-james-initiates-coverage-on-monopar-therapeutics-with-strong-buy-rating-announces-price-target-of-80
Raymond James Initiates Coverage On Monopa...
09/03/2025 16:49:58

Raymond James analyst Chris Raymond initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Strong Buy rating and an...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION